Patent US4237253A successfully refreshed from Google Patents.
Patent US4040904A successfully refreshed from Google Patents.
US4040904A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel rabies virus vaccine and processes
Assignee: Individual
•
Filing: 1975-07-21
•
Granted: 1977-08-09
•
Expires: 1995-07-21
Abstract
Abstract There is presented herein a novel rabies virus vaccine which has been developed from a known strain and a process for the preparation of the vaccine. One outstanding advantage of the novel strain is the direct correlation of its cytopathic effect on tissue culture cell monolayers and its titre.
Inventors
- 👤 Eban A. Slater
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 15:17
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/205; A61K2039/51; A61K2039/525; A61K2039/5254; A61K2039/55; A61K2039/552; C; C12; C12N; C12N2760/00; C12N2760/00011; C12N2760/20011; C12N2760/20111; C12N2760/20134; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
52 words
A method for the preparation of a novel live rabies virus strain which exhibits reproducibly significant cytopathic effect which correlates with the virus titer, said method comprising passing the ERA strain rabies virus in tissue culture of PK 2 A cells for a number of passages sufficient to develop said novel strain.
Claim 2
Independent Claim
52 words
A method for the preparation of a novel live rabies virus strain which exhibits reproducibly significant cytopathic effect which correlates with the virus titer, said method comprising passing the ERA strain rabies virus in tissue culture of PK 2 A cells for a number of passages sufficient to develop said novel strain.
Claim 3
Dependent Claim
20 words
The method of claim 1 wherein the passage through the PK 2 A cells is repeated at least 60 times.
Claim 4
Independent Claim
67 words
A method for the preparation of a novel live rabies virus exhibiting a reproducibly significant cytopathic effect in PK 2 A cells which correlates directly with the virus titer, suitable for immunizing animals against rabies, said method comprising passing the ERA strain rabies virus through tissue cultures of PK 2 A cells for at least 60 times and then passing said strain through primary canine kidney cells.
Claim 5
Independent Claim
67 words
A method for the preparation of a novel live rabies virus exhibiting a reproducibly significant cytopathic effect in PK 2 A cells which correlates directly with the virus titer, suitable for immunizing animals against rabies, said method comprising passing the ERA strain rabies virus through tissue cultures of PK 2 A cells for at least 60 times and then passing said strain through primary canine kidney cells.
Claim 6
Independent Claim
98 words
A method for the preparation of a novel live rabies virus exhibiting a reproducibly significant cytopathic effect in Pk 2 A cells which correlates with the virus titer, said method comprising inoculating cells of the PK 2 A cell line with the ERA strain live rabies virus, incubating said virus and cells in a tissue culture nutrient medium for a time sufficient for growth and multiplication of said virus, harvesting said virus and repeating said incubation and harvesting of said virus in at least 60 consecutive cultures of PK 2 A cells at intervals of about -7 days.
Claim 7
Independent Claim
98 words
A method for the preparation of a novel live rabies virus exhibiting a reproducibly significant cytopathic effect in Pk 2 A cells which correlates with the virus titer, said method comprising inoculating cells of the PK 2 A cell line with the ERA strain live rabies virus, incubating said virus and cells in a tissue culture nutrient medium for a time sufficient for growth and multiplication of said virus, harvesting said virus and repeating said incubation and harvesting of said virus in at least 60 consecutive cultures of PK 2 A cells at intervals of about -7 days.
Claim 8
Independent Claim
173 words
A method for the preparation of a novel rabies virus exhibiting a reproducibly significant cytopathic effect in PK 2 A cells which correlates with the virus titer and suitable for the immunizing of animals against rabies, said method comprising inoculating cells of a PK 2 A cell line with the ERA strain live rabies virus, incubating said virus and cells in a tissue culture medium at a temperature of about 32°-39° C. for a time sufficient for growth and multiplication of said virus, harvesting the virus, repeating said incubation and harvesting of said virus in at least 60 consecutive cultures at intervals of about 4- 7 days, inculating dog kidney cells with said virus, incubating said virus and cells in a tissue culture medium at a temperature of about 32°-39° C. for a time sufficient for growth and multiplication of said virus to take place, harvesting said virus from said dog kidney cells and repeating said incubation and harvesting of said virus for at least 5 consecutive cultures of said dog kidney cells.
Claim 9
Independent Claim
173 words
A method for the preparation of a novel rabies virus exhibiting a reproducibly significant cytopathic effect in PK 2 A cells which correlates with the virus titer and suitable for the immunizing of animals against rabies, said method comprising inoculating cells of a PK 2 A cell line with the ERA strain live rabies virus, incubating said virus and cells in a tissue culture medium at a temperature of about 32°-39° C. for a time sufficient for growth and multiplication of said virus, harvesting the virus, repeating said incubation and harvesting of said virus in at least 60 consecutive cultures at intervals of about 4- 7 days, inculating dog kidney cells with said virus, incubating said virus and cells in a tissue culture medium at a temperature of about 32°-39° C. for a time sufficient for growth and multiplication of said virus to take place, harvesting said virus from said dog kidney cells and repeating said incubation and harvesting of said virus for at least 5 consecutive cultures of said dog kidney cells.
References Cited (Backward Citations)
US3423505A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-08-08 | 1981-02-07 | 1981-08-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-08-08 | 1985-02-07 | 1985-08-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-08-08 | 1989-02-07 | 1989-08-09 | $7700.00 | Window Closed / Lapsed |